YC-1 suppresses constitutive nuclear factor-κB activation and induces apoptosis in human prostate cancer cells

Yao Ting Huang, Shiow Lin Pan, Jih Hwa Guh, Ya Ling Chang, Fang Yu Lee, Sheng Chu Kuo, Cheng Ming Teng

研究成果: 雜誌貢獻文章同行評審

44 引文 斯高帕斯(Scopus)


Although the indazole compound, YCA, is reported to exert anticancer activities in several cancer cell types, its target and mechanism of action have not been well explored. The objectives of this study were to ascertain whether YC-1 directly induces apoptosis in prostate cancer cells and to explore the mechanism(s) whereby YC-1 causes cell death. Hormone-refractory metastatic human prostate cancer PC-3 cells were selected for this study. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay indicated that YC-1 suppresses growth of PC-3 cells in a concentration-dependent and time-dependent manner. Apoptosis was determined using 4′,6-diamidino-2-phenylindole staining, and cell cycle progression was examined by FACScan flow cytometry. YC-1 treatment showed chromatin condensation and increased the percentage of PC-3 cells in the hypodiploid sub-G0-G1 phase, indicative of apoptosis. Additionally, exposure to YC-1 was found to induce activation of caspase-3 and cleavage of poly(ADP-ribose) polymerase. Translocation and activation of nuclear factor-κB (NF-κB) were determined by immunofluorescent staining and ELISA, respectively. The results showed that YC-1 abolished constitutive nuclear translocation and activation of NF-κB/p65. Furthermore, inhibition of inhibitor of κBα (IκBα) phosphorylation and accumulation of IκBα were observed. The antitumor effects of YC-1 were evaluated by measuring the growth of tumor xenografts in YC-1-treated severe combined immunodeficient mice. The volumes of PC-3 tumors produced in severe combined immunodeficient mice were observed to decline significantly after treatment with YCA compared with vehicle controls. We concluded that the antitumor effects of YC-1 in PC-3 cells include the induction of apoptosis and the suppression of NF-κB activation. Given these unique actions, further investigations of the effects of YC-1 against hormone-refractory prostate cancer are warranted.
頁(從 - 到)1628-1635
期刊Molecular Cancer Therapeutics
出版狀態已發佈 - 10月 2005

ASJC Scopus subject areas

  • 腫瘤科
  • 藥物發現
  • 藥理


深入研究「YC-1 suppresses constitutive nuclear factor-κB activation and induces apoptosis in human prostate cancer cells」主題。共同形成了獨特的指紋。